Wedam S, Fashoyin-Aje L, Gao X, Bloomquist E, et al. FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer. Clin Cancer Res 2020 Mar 26. pii: 1078-0432.CCR-19-3980.
PMID: 32217612